Narrow focus on vaccines COVID-19 Jean Bourbeau clinical trial

Narrow focus on COVID vaccines

Dr. Jean Bourbeau contributed to an article in The Star on September 29, 2020. He highlights how our narrow focus on vaccines during the COVID-19 pandemic is a risk we cannot afford. Combating this virus requires an array of good treatments, based on good science (randomized, placebo-controlled clinical trials). This include antivirals, plasma trials, corticosteroids, repurposing of old drugs to address the virus, in addition to vaccines. Dr. Bourbeau is working on a Phase III clinical trial of a repurposed generic drug developed by Pulmonem, a Canadian biotech start-up, which could provide a quick, safe and cost-effective treatment for COVID-19.

Read the article here:

Narrow focus on vaccines is a risk we can’t afford. The Star. by Dr. Jean Bourbeau. Sept 29, 2020.

Learn more about Dr. Bourbeau’s Phase III clinical trial:

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19.